These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 7621254)

  • 41. Making sense of antisense.
    Vidal L; Blagden S; Attard G; de Bono J
    Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy.
    Tidd DM
    Anticancer Res; 1990; 10(5A):1169-82. PubMed ID: 2241097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene-based therapy for hypertension--do preclinical data suggest a promising future?
    Puddu GM; Cravero E; Ferrari E; Muscari A; Puddu P
    Cardiology; 2007; 108(1):40-7. PubMed ID: 16968989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent status of the antisense oligonucleotide approaches in oncology.
    Ma L; Calvo F
    Fundam Clin Pharmacol; 1996; 10(2):97-115. PubMed ID: 8737953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antisense oligonucleotide derivatives as gene-targeted drugs.
    Knorre DG; Vlassov VV
    Biomed Sci; 1990 Apr; 1(4):334-43. PubMed ID: 1723003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated messenger RNA levels after antisense oligodeoxynucleotide treatment in vitro and in vivo.
    Probst JC; Skutella T
    Biochem Biophys Res Commun; 1996 Aug; 225(3):861-8. PubMed ID: 8780703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense therapy.
    Narayanan R; Akhtar S
    Curr Opin Oncol; 1996 Nov; 8(6):509-15. PubMed ID: 8971471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications.
    Calabretta B
    Cancer Res; 1991 Sep; 51(17):4505-10. PubMed ID: 1873794
    [No Abstract]   [Full Text] [Related]  

  • 49. In vitro and in vivo pharmacologic activities of antisense oligonucleotides.
    Mirabelli CK; Bennett CF; Anderson K; Crooke ST
    Anticancer Drug Des; 1991 Dec; 6(6):647-61. PubMed ID: 1663361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Prospects of antisense therapy technologies].
    Skoblov MIu
    Mol Biol (Mosk); 2009; 43(6):984-98. PubMed ID: 20088374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nucleic-acid therapeutics: basic principles and recent applications.
    Opalinska JB; Gewirtz AM
    Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology.
    Zon G
    Mol Neurobiol; 1995; 10(2-3):219-29. PubMed ID: 7576309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Making sense of antisense.
    Murakami A
    Trends Mol Med; 2001 Oct; 7(10):430-1. PubMed ID: 11597507
    [No Abstract]   [Full Text] [Related]  

  • 54. Role of biological therapies in the development of personalized medicine.
    Jain KK
    Expert Opin Biol Ther; 2012 Jan; 12(1):1-5. PubMed ID: 22107592
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Approach to human glioma cells using antisense molecules].
    Yoshida S; Tanaka R
    No To Shinkei; 1995 Sep; 47(9):823-8. PubMed ID: 7546930
    [No Abstract]   [Full Text] [Related]  

  • 56. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
    Warzocha K; Wotowiec D
    Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Special feature: A survey of the recent patent literature on the delivery of genes and oligonucleotides.
    Mrsny RJ
    J Drug Target; 1999; 7(1):1-10. PubMed ID: 10614811
    [No Abstract]   [Full Text] [Related]  

  • 58. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides.
    Akhtar S
    J Drug Target; 1998; 5(4):225-34. PubMed ID: 9713973
    [No Abstract]   [Full Text] [Related]  

  • 60. [Anti-HIV genes: strategies for gene therapy of AIDS].
    Shimada T
    Nihon Rinsho; 1993 Sep; 51 Suppl():229-34. PubMed ID: 8271389
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.